Signal transducer CD24 (CD24) (CD24)

Signal transducer CD24 (CD24) is a highly glycosylated glycosylphosphatidylinositol (GPI)-anchored surface protein that plays a significant role in cell-cell and cell-matrix interactions, as well as in the regulation of B-cell proliferation and T-cell activation (UniProt P25063). In the context of oncology, CD24 is recognized as a potent "don't eat me" signal, similar to CD47, which interacts with Sialic acid-binding Ig-like lectin 10 (Siglec-10) expressed on tumor-associated macrophages to inhibit phagocytosis (Barkal et al., 2019, Nature). CD24 is overexpressed in a wide variety of human malignancies, including breast, ovarian, lung, and pancreatic cancers, where its expression often correlates with poor prognosis and increased metastatic potential. Therapeutic strategies targeting CD24, such as the monoclonal antibody 3D128 (developed by 3D Medicines), aim to disrupt the CD24-Siglec-10 signaling axis. By blocking this interaction, these drugs enhance the phagocytic clearance of tumor cells by macrophages and may stimulate a broader anti-tumor immune response. Clinical development of CD24-targeted therapies is ongoing, with a focus on overcoming immune evasion in the tumor microenvironment (3D Medicines Patent WO2021155814A1). Beyond oncology, CD24 is also investigated for its role in inflammatory and autoimmune diseases due to its ability to modulate the innate immune response.

Other names

CD24 antigenSmall cell lung carcinoma cluster 4 antigenNectadrinSignal transducer CD24Heat-stable antigen

3D128 is a monoclonal antibody that binds to CD24 on tumor cells, blocking its interaction with Siglec-10 on macrophages, thereby promoting antibody-dependent cellular phagocytosis (ADCP) and inhibiting immune evasion.